Literature DB >> 21190087

Causation and melanoma classification.

Brendan Clarke1.   

Abstract

In this article, I begin by giving a brief history of melanoma causation. I then discuss the current manner in which malignant melanoma is classified. In general, these systems of classification do not take account of the manner of tumour causation. Instead, they are based on phenomenological features of the tumour, such as size, spread, and morphology. I go on to suggest that misclassification of melanoma is a major problem in clinical practice. I therefore outline an alternative means of classifying these tumours based on causal factors. By analogy with similar systems that have recently emerged for other cancers, I suggest that this causal classification is likely to be both workable and helpful, even in the absence of a full causal-mechanistic understanding of the aetiology of the tumour.

Entities:  

Mesh:

Year:  2011        PMID: 21190087     DOI: 10.1007/s11017-010-9168-3

Source DB:  PubMed          Journal:  Theor Med Bioeth        ISSN: 1386-7415


  22 in total

1.  Progression of human cutaneous melanoma is associated with loss of expression of c-kit proto-oncogene receptor.

Authors:  P G Natali; M R Nicotra; A B Winkler; R Cavaliere; A Bigotti; A Ullrich
Journal:  Int J Cancer       Date:  1992-09-09       Impact factor: 7.396

2.  Malignant melanomas of the skin. A study of the origin, development, aetiology, spread, treatment, and prognosis.

Authors:  N C PETERSEN; D C BODENHAM; O C LLOYD
Journal:  Br J Plast Surg       Date:  1962-04

3.  Major response to imatinib mesylate in KIT-mutated melanoma.

Authors:  F Stephen Hodi; Philip Friedlander; Christopher L Corless; Michael C Heinrich; Suzanne Mac Rae; Andrea Kruse; Jyothi Jagannathan; Annick D Van den Abbeele; Elsa F Velazquez; George D Demetri; David E Fisher
Journal:  J Clin Oncol       Date:  2008-04-20       Impact factor: 44.544

4.  Distinct sets of genetic alterations in melanoma.

Authors:  John A Curtin; Jane Fridlyand; Toshiro Kageshita; Hetal N Patel; Klaus J Busam; Heinz Kutzner; Kwang-Hyun Cho; Setsuya Aiba; Eva-Bettina Bröcker; Philip E LeBoit; Dan Pinkel; Boris C Bastian
Journal:  N Engl J Med       Date:  2005-11-17       Impact factor: 91.245

5.  Thickness, cross-sectional areas and depth of invasion in the prognosis of cutaneous melanoma.

Authors:  A Breslow
Journal:  Ann Surg       Date:  1970-11       Impact factor: 12.969

6.  Biomarker expression and risk of subsequent tumors after initial ductal carcinoma in situ diagnosis.

Authors:  Karla Kerlikowske; Annette M Molinaro; Mona L Gauthier; Hal K Berman; Fred Waldman; James Bennington; Henry Sanchez; Cynthia Jimenez; Kim Stewart; Karen Chew; Britt-Marie Ljung; Thea D Tlsty
Journal:  J Natl Cancer Inst       Date:  2010-04-28       Impact factor: 13.506

7.  Estimates of stage-specific survival are altered by changes in the 2002 American Joint Committee on Cancer staging system for melanoma.

Authors:  Leah Ben-Porat; Katherine S Panageas; Christine Hanlon; Ami Patel; Allan Halpern; Alan N Houghton; Daniel Coit
Journal:  Cancer       Date:  2006-01-01       Impact factor: 6.860

Review 8.  Epidemiology of melanoma.

Authors:  R Marks
Journal:  Clin Exp Dermatol       Date:  2000-09       Impact factor: 3.470

9.  A lost piece of melanoma history.

Authors:  K Denkler; J Johnson
Journal:  Plast Reconstr Surg       Date:  1999-12       Impact factor: 4.730

Review 10.  Recent progress in understanding the pathology of malignant melanoma.

Authors:  Silke Kuphal; Anja Bosserhoff
Journal:  J Pathol       Date:  2009-12       Impact factor: 7.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.